Boehringer launches new purification technology for Ingelvac CircoFLEX®
Drug firm Boehringer Ingelheim has announced new purification technology for Ingelvac CircoFLEX®.
Pharmaceutical firm Boehringer Ingelheim has announced a new and proprietary purification process for its swine vaccine, Ingelvac CircoFLEX®.
Ingelvac CircoFLEX® was the first PCV2 (porcine circovirus type 2) that could be mixed with an M hyo vaccine to address two critical swine pathogens in a single dose. Considered to be the most revolutionary PCV2 vaccines on the market, it provides effective control of circovirus-associated disease in pigs aged three weeks and older.
The new diafiltration process, named DiaTEC, removes residual cell media components from the virus-like particles (VLPs) to obtain highly immunogenic and non-virucidal vaccine.
A press release reads: “With DiaTEC, a new and proprietary diafiltration technology, Ingelvac CircoFLEX® becomes the first and only non-virucidal PCV2 vaccine for improved capabilities to be freshly mixed on farm.”
Eva Joras, global brand manager at Boehringer Ingelheim, said: “I am really proud that we continuously invest in our research and development to further improve our leading products to address our customers’ needs.”
Ingelvac CircoFLEX®, manufactured with the new technology, will be launched in several different packaging sizes in all EU countries in January 2020.
Eligible members of BEVA will be able to vote for their Council team until Monday, 17 August 2026. Members will have received an election email on 17 July.
